Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.17944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Palak J Trivedi und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Centre for Liver and Gastrointestinal Research and Gast…. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Cholangiopancreatography, Magnetic Resonance. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, National Institute for Health Research.
Abstract (Originalsprache)
Background
Imaging markers of biliary disease in primary sclerosing cholangitis (PSC) have potential for use in clinical and trial disease monitoring. Herein, we evaluate how quantitative magnetic resonance cholangiopancreatography (MRCP) metrics change over time, as per the natural history of disease.
Methods
Individuals with PSC were prospectively scanned using non‐contrast MRCP. Quantitative metrics were calculated using MRCP+ post‐processing software to assess duct diameters and dilated and strictured regions. Additionally, a hepatopancreatobiliary radiologist (blinded to clinical details, biochemistry and quantitative biliary metrics) reported each scan, including ductal disease assessment according to the modified Amsterdam Cholangiographic Score (MAS).
Results
At baseline, 14 quantitative MRCP+ metrics were found to be significantly different in patients with PSC ( N = 55) compared to those with primary biliary cholangitis ( N = 55), autoimmune hepatitis ( N = 57) and healthy controls ( N = 18). In PSC specifically, baseline metrics quantifying the number of strictures and the number and length of bile ducts correlated with the MAS, transient elastography and serum ALP values ( p < 0.01 for all correlations). Over a median 371‐day follow‐up (range: 364–462), 29 patients with PSC underwent repeat MRCP, of whom 15 exhibited quantitative changes in MRCP+ metrics. Compared to baseline, quantitative MRCP+ identified an increasing number of strictures over time ( p < 0.05). Comparatively, no significant differences in biochemistry, elastography or the MAS were observed between timepoints. Quantitative MRCP+ metrics remained stable in non‐PSC liver disease.
Conclusion
Quantitative MRCP+ identifies changes in ductal disease over time in PSC, despite stability in biochemistry, liver stiffness and radiologist‐derived cholangiographic assessment (trial registration: ISRCTN39463479).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Centre for Liver and Gastrointestinal Research and Gastrointestinal Research, National Institute of Health Research (NIHR) Bi…
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
- Liver Unit, University Hospitals Birmingham Queen Elizabeth, Birmingham, UK.
- Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
- Perspectum Ltd, Oxford, UK.
- NIHR Nottingham BRC, University of Nottingham, Nottingham, UK.
ORCID-Profile: Palak J Trivedi, Gideon M Hirschfield
Förderung
- National Institute for Health and Care Research
- National Institute for Health Research
Zitieren
APA
Trivedi, P. J., Arndtz, K., Abbas, N., Telford, A., Young, L., Banerjee, R., Eddowes, P., Jhaveri, K. S., & Hirschfield, G. M. (2024). Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17944
Vancouver
Trivedi PJ, Arndtz K, Abbas N, Telford A, Young L, Banerjee R, et al. Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17944
BibTeX
@article{Trivedi2024,
author = {Trivedi, Palak J and Arndtz, Katherine and Abbas, Nadir and Telford, Alison and Young, Liam and Banerjee, Rajarshi and Eddowes, Peter and Jhaveri, Kartik S and Hirschfield, Gideon M},
title = {Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.17944}
}
EUVIMED